# A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Study · id `cardio:ct-nct01018173` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01018173](<https://clinicaltrials.gov/study/NCT01018173>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01018173

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2118 participants.

## Technical summary

Registry record NCT01018173. Randomized; double masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2011-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2118 participants (enrolled count; ClinicalTrials.gov record NCT01018173, source copy `cardio:ctgov-nct01018173-2016-11-02`, retrieved 2026-10-26)
- Start date: 2010-01 (registry gives no type) (ClinicalTrials.gov record NCT01018173, source copy `cardio:ctgov-nct01018173-2016-11-02`, retrieved 2026-10-26)
- Primary completion: 2011-01 (actual) (ClinicalTrials.gov record NCT01018173, source copy `cardio:ctgov-nct01018173-2016-11-02`, retrieved 2026-10-26)
- Completion: 2011-01 (actual) (ClinicalTrials.gov record NCT01018173, source copy `cardio:ctgov-nct01018173-2016-11-02`, retrieved 2026-10-26)
- Countries: United States; Australia; Brazil; Bulgaria; Canada; Czechia; Denmark; Estonia; Germany; Hungary; India; Israel; Lithuania; Malaysia; Mexico; Poland; Romania; Russia; Slovakia; South Africa; Spain; Taiwan; Thailand; Ukraine; United Kingdom (ClinicalTrials.gov record NCT01018173, source copy `cardio:ctgov-nct01018173-2016-11-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01018173-2016-11-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease
- Condition: Diabetes Mellitus Type 2
- Intervention (Drug): placebo
- Intervention (Drug): taspoglutide
- Lead sponsor: Hoffmann-La Roche
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Hoffmann-La Roche (`cardio:org-hoffmann-la-roche`)

## Provenance

Content hash: 2cc7965c34c3ec445f6f53a2be3ea52d4181349ce1336503b671f0f91b14dbf4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
